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Tremulous jaw movements (TJMs) are rapid vertical deflections of the lower jaw
that resemble chewing but are not directed at any particular stimulus. In rodents,
TJMs are induced by neurochemical conditions that parallel those seen in human
Parkinsonism, including neurotoxic or pharmacological depletion of striatal dopamine
(DA), DA antagonism, and cholinomimetic administration. Moreover, TJMs in rodents can
be attenuated by antiparkinsonian agents, including levodopa (L-DOPA), DA agonists,
muscarinic antagonists, and adenosine A2A antagonists. In human Parkinsonian patients,
exaggerated physiological synchrony is seen in the beta frequency band in various parts
of the cortical/basal ganglia/thalamic circuitry, and activity in the tremor frequency range
(3–7 Hz) also has been recorded. The present studies were undertaken to determine if
tremor-related local field potential (LFP) activity could be recorded from motor cortex (M1)
or subthalamic nucleus (STN) during the TJMs induced by the muscarinic agonist
pilocarpine, which is a well-known tremorogenic agent. Pilocarpine induced a robust
TJM response that was marked by rhythmic electromyographic (EMG) activity in the
temporalis muscle. Compared to periods with no tremor activity, TJM epochs were
characterized by increased LFP activity in the tremor frequency range in both neocortex
and STN. Tremor activity was not associated with increased synchrony in the beta
frequency band. These studies identified tremor-related LFP activity in parts of the
cortical/basal ganglia circuitry that are involved in the pathophysiology of Parkinsonism.
This research may ultimately lead to identification of the oscillatory neural mechanisms
involved in the generation of tremulous activity, and promote development of novel
treatments for tremor disorders.
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INTRODUCTION
Parkinsonism is a broad family of disorders that includes idiopathic Parkinson’s disease (PD), which
results from degeneration of nigrostriatal dopamine (DA) neurons (Hornykiewicz, 1973), and
drug-induced Parkinsonism, which is induced by drugs that interfere with DA transmission (e.g.,
DA antagonists, DA depleting agents; Marsden et al., 1975; McEvoy, 1983), and cholinomimetics
such as anticholinesterases and muscarinic agonists (Ott and Lannon, 1992; Aarsland et al., 2003).
Frontiers in Behavioral Neuroscience | www.frontiersin.org 1 June 2016 | Volume 10 | Article 123
Long et al. Tremor-Related Brain Field Potentials
The cardinal motor symptoms of Parkinsonism include akinesia,
bradykinesia, rigidity, and a resting tremor that typically
occurs in the 3–7 Hz frequency range (Marsden et al., 1975).
Motor dysfunctions resembling drug-induced Parkinsonism
are produced in rodents by the same pharmacological agents
that induce human Parkinsonism, and resting tremor can be
modeled in rodents using the tremulous jaw movement (TJM)
model. TJMs, which are defined as ‘‘rapid, repetitive vertical
deflections of the lower jaw that resemble chewing but are not
directed at any particular stimulus’’ (Salamone et al., 1998), have
a local frequency of 3–7 Hz, which parallels that of Parkinsonian
resting tremor (Cousins et al., 1998; Salamone et al., 1998, 2015a;
Collins et al., 2010; Podurgiel et al., 2013b). TJMs are induced
by neurotoxic or pharmacological depletion of striatal DA, DA
antagonism, and cholinomimetic drugs (Jicha and Salamone,
1991; Salamone et al., 1998; Podurgiel et al., 2013a,b, 2015;
Gandía et al., 2015), and can be attenuated by co-administration
of antiparkinsonian agents such as levodopa (L-DOPA), DA
agonists, muscarinic antagonists,MAO inhibitors, and adenosine
A2A antagonists (Cousins et al., 1997; Simola et al., 2004, 2006;
Salamone et al., 2005, 2008a,b, 2015a,b; Podurgiel et al.,
2013a,b). Considerable evidence indicates that TJMs in rodents
are a valid model for the exploration of the pharmacology,
neurochemistry and physiology of drug-induced tremor
(Salamone et al., 1998, 2008b, 2013, 2015a; Collins-Praino et al.,
2011; Podurgiel et al., 2013a,b, 2015; Herrera-Meza et al., 2014;
Gandía et al., 2015).
One method that can be used for studying the neural
mechanisms underlying tremorogenesis is to record fluctuations
in the electrical activity of the brain, such as local field
potentials (LFPs). Measures of LFP activity provide a way
to characterize the synchronous oscillatory neural activities
that are potentially related to motor dysfunctions. Exaggerated
neuronal synchrony has been recorded in basal ganglia and
cortex of PD patients, with the beta band (∼15–30 Hz) being
the best-characterized oscillation (Brown, 2003; Hammond et al.,
2007; Oswal et al., 2013). Increased beta activity has been
observed in the cortex (George et al., 2013) and subthalamic
nucleus (STN) of PD patients, and it has been suggested that
excessive synchrony in this frequency range contributes to
motor dysfunction (Levy et al., 2002; Brown and Williams,
2005; Kühn et al., 2006). Reductions in STN beta activity
correlate with improvements in akinesia and rigidity in PD
patients (Levy et al., 2002; Kühn et al., 2006). While the
literature supports a link between increased cortical and basal
ganglia beta power and the development of akinesia/rigidity,
beta activity generally does not correlate with the severity of
resting tremor (Kühn et al., 2005; Hammond et al., 2007;
Oswal et al., 2013). Rather, the development of tremor in
PD patients was shown to be associated with the emergence
of oscillations in the tremor frequency range (3–7 Hz) in
the cortex and basal ganglia (Timmermann et al., 2003;
Reck et al., 2009; Hirschmann et al., 2013; Oswal et al.,
2013). Timmermann et al. (2003) reported strong coherence
between electromyograph (EMG) activity of forearm muscles
and activity in the contralateral primary motor cortex (M1),
at tremor (3–7 Hz) and double tremor frequency (7–13 Hz)
in PD patients off medication. Similar patterns of activity have
been observed in the STN of PD patients, revealing power
spectra peaks at tremor frequency and tremor harmonics,
as well as significant coherence between STN LFPs and
EMG activity at tremor frequency (Levy et al., 2000; Brown
et al., 2001; Liu et al., 2002; Wang et al., 2005; Reck et al.,
2009).
These clinical reports support the idea that cortical and
STN power and coherence at tremor frequencies increases with
the manifestation of tremor, but this phenomenon has not
been modeled extensively in rodents. Therefore, the present
study characterized the temporal pattern of oral EMG activity
and associated changes in LFPs recorded from M1 and
STN during the TJMs induced by the muscarinic agonist
pilocarpine. Pilocarpine was selected for these studies because
our laboratory has a large data base on the pharmacology of
cholinomimetic-induced TJMs, including studies demonstrating
that these movements can be attenuated by co-administration
of antiparkinsonian drugs (Salamone et al., 1998, 2013; Collins
et al., 2010; Collins-Praino et al., 2013).
MATERIALS AND METHODS
Animals
A total of five adult male Sprague Dawley rats (Harlan Sprague
Dawley, Indianapolis, IN, USA) with no prior drug experience
were used in the present experiment. The rats weighed 350–450 g
during the course of the experiment and had ad libitum access to
lab chow and water. Animals were group-housed prior to surgery
in a colony that was maintained at approximately 23◦C and had a
12-h light/dark cycle (lights on at 0700 h). Post-surgery, animals
were single housed to avoid over grooming around the surgical
implant.
Drug Treatment Procedures and Dose
Selection
Pilocarpine was purchased from Sigma Aldrich Chemical
(St. Louis, MO, USA) and dissolved in 0.9% saline. The dose
of pilocarpine (4.0 mg/kg) was based on previous experiments
showing significant induction of jaw movements at this dose (for
further details, see Collins et al., 2010).
Surgical Procedures
Ethics Statement
All procedures performed were in strict accordance with the
guidelines and regulations implemented by the University of
Connecticut’s Institutional Animal Care and Use Committee and
NIH. The protocol was approved by the Institutional Animal
Care and Use Committee of the University of Connecticut
(Protocol Number: A15–014) and all efforts were made to
minimize suffering.
Rats were anesthetized with a 1.0 ml/kg IP injection
of a cocktail solution containing 10.0 ml of 100 mg/mL
ketamine plus 0.75 ml of 20.0 mg/ml xylazine (Phoenix
Scientific, Inc., St. Joseph, MO, USA). Rats were placed in a
stereotaxic frame (Kopf, Tujunga, CA, USA), and a midline
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scalp incision was made. Two electrode arrays consisting of
50 µm tungsten wire (California Fine Wire Company, Grover
Beach, CA, USA) were bilaterally implanted with a 27-gauge
needle approximately 5.0 mm deep into the lateral temporalis
muscle (four EMG electrodes per animal). Previous research
has demonstrated that the lateral temporalis muscle is the
jaw muscle that shows activity most closely related to TJMs
(Cousins et al., 1998). Burr holes were drilled through the skull
over the STN (R hemisphere) and M1 (L hemisphere), and
2–4 electrode arrays were implanted (eight LFP electrodes per
animal). LFP electrode arrays were comprised of four linearly
spaced 50 µm tungsten wires (California Fine Wire Company,
Grover Beach, CA, USA). Electrode wire was arranged and
separated by fused silica tubing (Polymicro Tubing, Phoenix,
AZ, USA), attached to female pins (Omnetics, Minneapolis,
MN, USA) and secured in a rectangular five by four pin array.
Two stainless steel watch screws driven into the skull above
the cerebellum served as indifferent and ground electrodes.
Supplementary anchor screws were positioned as necessary
and the entire head-stage ensemble was fortified with dental
acrylic. The surgical coordinates, for which Bregma and the
top of the skull was used as the reference point, were as
follows: STN (AP: −3.6, ML: ± 2.5, DV: −7.5); M1 (AP: +1.0,
ML: +1.9, DV: −2.5). Rats recovered for 1 week post-surgical
procedure.
Behavioral Measures
Following a one-week recovery period, rats were given an
acute IP injection of saline (vehicle). Immediately after vehicle
injection, rats were placed into a Plexiglas observation chamber
and allowed to habituate for 10 min. At the beginning of this
habituation period, the animals were connected to the recording
apparatus by a multi-channel tether (Neuralynx, Bozeman,
MT, USA) that was attached to a pulley system in the ceiling.
Following the habituation period, a trained observer counted
TJMs for 15 min. TJMs were defined as rapid vertical deflections
of the lower jaw that resembled chewing but were not directed at
any particular stimulus (Salamone et al., 1998). At the end
of the 15-min observation period, rats were disconnected
and returned to their home cages. This procedure was
repeated with administration of 4.0 mg/kg pilocarpine
24 h later.
Electrophysiological Data Acquisition and
Analysis
Following the habituation period, wide-band electrical activity
was recorded (5050.5 samples/s) for 15 min using a Neuralynx
data acquisition system (Bozeman, MT, USA). TJMs were
counted simultaneously by a trained observer and noted
using event markers through Cheetah data acquisition software
(version 5.6.3; Neuralynx, Bozeman, MT, USA). Following
data acquisition and during subsequent offline analysis, data
were imported into Matlab R2014a (Mathworks, Natick,
MA, USA).
The raw EMG signal was bandpass filtered between 500
and 1500 Hz and the Hilbert transform, which provides
an analytic representation of the signal, was computed on
the bandpass filtered signal using Matlab. In this regard,
the instantaneous (5050.5 samples/s) EMG envelope amplitude
(magnitude of Hilbert transform) was obtained over time.
The EMG signal was then full wave rectified, to generate the
absolute value of signal, and all raw EMG traces presented in
the current analysis represent this full wave rectified signal. Event
markers (as denoted in Cheetah data acquisition software) were
simultaneously imported into Matlab and plotted along with the
EMG signal. The presence or absence of these event markers
was used to identify TJM and no TJM epochs, respectively.
Raw LFP data were imported into Matlab R2014a and down-
sampled by a factor of 10 during offline analysis, thus changing
the sampling rate to 505.05 samples/s (Hz; 5050.5/10 = 505.05).
The raw LFP signal was lowpass filtered to remove high
frequency chewing, chattering and/or teeth grinding artifacts
(Fc = 250 Hz). Then, the LFP signal was bandpass filtered
for tremor (3–7 Hz) and beta frequency (15–30 Hz) and the
Hilbert transformwas computed on the bandpass filtered signals.
Data were examined during: (1) TJM epochs; and (2) No TJM
epochs.
All data analysis was conducted using custom written
programs in MatLab R2014a (Mathworks, Natick, MA, USA).
Power spectral density estimates were obtained using Welch’s
averaged modified periodogram method (Welch, 1967) during
epochs of TJMs and no TJMs. To extract the amplitude
modulation (AM) frequency of the EMG signal (e.g., ‘‘tremor
frequency’’, 3–7 Hz), power spectral density estimates were
obtained from the envelope (magnitude of Hilbert transform) of
the bandpass filtered EMG signal. For LFP data, the power for
tremor (3–7 Hz) and beta frequency (15–30 Hz) was calculated
from the bandpass filtered signals and represented in units
of mV2. Average power was calculated by taking the sum of
the power values within a given frequency range of interest
(e.g., 3–7 Hz) and multiplying the sum by the spectral window
resolution. LFP centroid frequency (i.e., the weighted mean
frequency) was calculated by first isolating the frequency range
of interest (e.g., 3–7 Hz), indexing the power values within that
frequency range and multiplying them. Then, we divided those
values by the sum of the previously indexed power values. Lastly,
we took the sum of the aforementioned (see for formula below
for calculation of centroid frequency).
C =
∑N−1
n = 0 f (n)x(n)∑N−1
n = 0 x(n)
(1)
Statistical Analyses
Comparisons between the total number of TJMs observed after
injections of vehicle and pilocarpine were performed using
the repeated measures t-test. Although vehicle conditions were
used to verify the ability of pilocarpine to produce TJMs, large
differences existed between vehicle and pilocarpine recordings
that made electrophysiological comparisons between these two
signals unsuitable. Essentially, vehicle treatments produce no
tremor bursts, but more movement artifact. Because of these
differences, all EMG and LFP data analysis were conducted on
epochs of TJMs and no TJMs within the pilocarpine recording
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for each animal. For each of the five animals a representative 2.2 s
TJM was identified by a trained observer using event markers.
The TJM length was determined by the lowest responding
animal. Further, within the same recording for each animal a
subsequent 2.2 s no TJM time point was isolated as indicated by
lack of event markers. For each electrode, the average LFP power
and centroid frequency was computed within the frequency
range of interest (3–7 Hz and 15–30 Hz) for TJM and no TJM
epochs all the while discretized by electrode location (M1 and
STN). Paired samples t-tests were computed to asses if there
were significant differences in: (1) average tremor LFP power
during TJMs and no TJMs for M1; (2) average tremor LFP
power during TJMs and no TJMs for STN; (3) average beta
LFP power during TJMs and no TJMs for M1; (4) average
beta LFP power during TJMs and no TJMs for STN; and
(5) the same as 1–4, but for centroid frequency. Further,
we computed paired-samples t-tests to examine if there were
differences in the aforementioned indices as a function of
brain area (M1 and STN). Lastly, paired samples t-tests were
used to confirm significant differences in number of TJMs
per 15 min recording period across vehicle and pilocarpine
recordings.
Histology
At the completion of the experiment, animals were deeply
anesthetized with CO2 and perfused with 0.9% physiological
saline followed by 3.7% formaldehyde solution. The brains
were extracted and stored in the formaldehyde solution for
1 week. Then, brains were sliced (50 µm sections) using
a vibratome (Leica, Germany), mounted, Nissl stained using
Cresyl Violet and cover-slipped allowing for verification of
electrode placements. Photomicrographs of electrode tracks
were taken using a Nikon microscope connected to a Spot
RT camera system, digitized and prepared for presentation
using Adobe Photoshop. Consistent with the histological
criteria employed by Brown et al. (2011) only placements
that were within 500 µm of the STN, but dorsal to the
cerebral peduncles and internal capsule were used for statistical
analyses.
RESULTS
Histological Verification of Electrode
Placements
A total of 38 LFP electrodes (n = 19 M1 electrodes; n = 19
STN electrodes) and five EMG electrodes across five animals
were used in the current analysis (see Supplementary Figure S1
for histology across all animals; atlas templates modified from
Paxinos and Watson, 2014). All animals contributed one EMG
electrode, 3–4 M1 (Figure 1A) and 3–4 STN (Figure 1B)
electrodes. All EMG and LFP data were simultaneously recorded
from each animal. M1 electrodes terminated in all cortical layers
but were more likely to terminate in deeper layers. Further, most
STN electrodes were hits, although a few terminated slightly
dorsally or anteriorly (data not shown), but still within the
500 µm criteria put forth by Brown et al. (2011).
Pilocarpine Induces TJMs in the Tremor
Frequency Range (3–7 Hz) as Reflected by
EMG
Administration of pilocarpine significantly induced TJMs
compared to vehicle control (Mean± SEM; Pilo: 603.6± 140.62;
Vehicle: 14.4 ± 4.4; t(4) = 4.3, p < 0.05). As described above,
all EMG and LFP data analysis were conducted on epochs of
TJMs vs. no TJMs within the pilocarpine recording for each
animal. During bouts of jaw movement activity, the bandpass
filtered (500–1500 Hz) and full wave rectified EMG signal was
marked by rhythmic activity in the 3–7 Hz range (Figure 2A
top, left; red). Conversely, during periods of quiescence, no
rhythmic activity was observed in the EMG (Figure 2A bottom,
left; blue). Spectrograms of the raw and unfiltered signals
indicated the same pattern of activity as the filtered EMG traces
(Figure 2A, right). For the traces presented in Figure 2A,
power spectral analysis revealed strong rhythmicity in the
envelope of the EMG signal with a fundamental frequency of
4 Hz along with robust 2nd and 3rd harmonics (Figure 2B,
red). Epochs of quiescence failed to exhibit AM of the EMG
signal within the tremor frequency range (Figure 2B, blue)
and show relatively little power overall. Upon examination of
the entire pilocarpine recording for the same representative
animal, rodents continued to exhibit dominant power of the
EMG envelope within the tremor frequency range, although
the harmonics were largely attenuated (Figure 2C). On average,
animals spent 13.39% of the 15-min recording session exhibiting
TJMs (Figure 2C, right) indicating the robustness of the observed
phenomenon.
Power in the Tremor Frequency Band
Increases during TJMs in M1 and STN
Upon examination of simultaneously recorded M1 LFPs for
the same animal as in Figure 2, the raw (Figure 3A top)
and bandpass filtered (3–7 Hz; Figure 3A middle) LFP signals
revealed increased power in the tremor frequency band during
epochs of TJMs (Figure 3A left, red), but not during bouts
of quiescence (Figure 3A right, blue). The LFP signal was
indexed during epochs of TJMs and no TJMs as indicated by
EMG event markers or lack thereof, respectively. Spectrograms
of the raw and unfiltered signal revealed differential patterns
of LFP activity for bouts of TJMs and quiescence (Figure 3A
bottom). The power spectrum of the raw LFP signal filtered
for tremor frequencies (3–7 Hz) during epochs of TJMs
(Figure 3A right, red) and no TJMs (Figure 3A right, blue)
indicated strong LFP power in the tremor range with a
peak at ∼4 Hz for bouts of TJMs, while little LFP power
existed at such frequencies for bouts lacking TJMs. At a
simultaneously recorded STN site, the same pattern of activity
was present (Figure 3B). Overall, the bandpass filtered LFP
signal (3–7 Hz) during bouts of TJMs and the subsequent power
spectrum of that signal revealed strong power in the 3–7 Hz
range, whereas bouts of quiescence did not exhibit this effect
(Figure 3B).
Summary data from all animals revealed the same pattern
of effects. Overall, M1 LFPs during TJM epochs (red) exhibited
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FIGURE 1 | Verification of electrode placements. (A, top): Photomicrographs of four representative and simultaneously recorded sites in motor cortex (M1).
Middle and right photomicrographs show 4× and 10× close-up of electrode tips, respectively. (A, bottom): Same as (A, top) but for a different animal. (B, top):
Photomicrographs of a representative recording site in subthalamic nucleus (STN). Middle and right photomicrographs show a 4× and 10× close-up of electrode
tips, respectively. (B, bottom): Same as (B, top) but for a different animal.
significantly more power in the 3–7 Hz range as compared to
no TJM (blue) epochs (Figure 3C, left; t(18) = 5.13, p < 0.05).
The same pattern of activity existed for STN recording sites
(Figure 3C, right; t(18) = 4.55, p < 0.05). Further, M1 exhibited
more power in the tremor band during TJM and no TJM
epochs compared to STN (TJM: t(18) = 3.47, p < 0.05; no
TJM: t(18) = 3.26, p < 0.05). Analysis of centroid frequency
(Figure 3D) revealed no differences between bouts of TJMs and
no TJMs within a given brain area (e.g., M1 TJM vs. M1 no TJM;
M1: t(18) = −0.79, p > 0.05; STN: t(18) = −0.36, p > 0.05).
Moreover, there were no significant differences in LFP centroid
frequency between TJM and no TJM epochs across brain areas
(e.g., M1 TJM vs. STN TJM; TJM: t(18) = 0.51, p> 0.05; No TJM:
t(18) = 1.88, p> 0.05).
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 June 2016 | Volume 10 | Article 123
Long et al. Tremor-Related Brain Field Potentials
FIGURE 2 | Pilocarpine induces Tremulous jaw movements (TJMs) in the tremor frequency range as reflected by electromyograph (EMG) activity.
(A, top): EMG electrode trace bandpass filtered for EMG frequency (500–1500 Hz) and full wave rectified during a long epoch of TJMs (red; 7.3 s) for a representative
animal. The spectrogram (right) indicates the same pattern of rhythmic activity as the EMG trace. (A, bottom): Same animal and recording time point as presented in
(A), but for a long period of quiescence (blue; 7.3 s). The spectrogram of raw and unfiltered signal (right) indicates little rhythmic activity during bouts lacking TJMs.
(B) Power spectrum of the EMG envelope (i.e., a smoothed curve outlining the extremes of the signal) for the same traces as presented in (A). As can be seen, there
is clear 3–7 Hz rhythmicity and strong harmonics during TJM epochs (red), which is absent during periods of quiescence (blue). (C, left): Power spectrum of the
entire pilocarpine recording (sans TJM and no TJM epoch isolation) for the same animal as presented in (A,B). (C, right): Behavior summarized across all animals for
the entirety of the pilocarpine recording.
Beta Band Power does not Increase during
TJMs in M1 and STN
Simultaneously recorded M1 LFPs for the animal shown in
Figures 2, 3, revealed similar LFP beta band power during
epochs of TJMs (Figure 4A left, red) and epochs of quiescence
(Figure 4A right, blue) for the raw (Figure 4A top) and bandpass
filtered (15–30 Hz; Figure 4A middle/bottom) LFP signals.
Importantly, the data shown here are for the same time points
as presented in Figures 2, 3, but here data were filtered for beta
(15–30 Hz) instead of tremor frequencies (3–7 Hz). A closer
look at the signal revealed similar instantaneous fluctuations
in the LFP during active (Figure 4A bottom, left) and quiet
(Figure 4A bottom, right) bouts. The power spectrum of the raw
LFP signal filtered for beta band activity during epochs of TJMs
(red) and no TJMs (blue) revealed strong LFP beta band power,
but no alterations in power across behavioral state (e.g., bouts
of TJMs vs. no TJMs; Figure 4A, right). At a simultaneously
recorded STN site, the same pattern of activity was present
(Figure 4B). Overall, the bandpass filtered LFP signal (15–30 Hz)
and subsequent power spectrum of that signal during epochs of
TJMs and quiescence revealed no differences in beta band power
(Figure 4B).
Summary data from all animals demonstrate the same trend
as represented in Figures 4A,B. Overall, M1 LFPs during TJM
epochs (red) and no TJM epochs (blue) exhibited similar levels
of beta band power (Figure 4C; t(18) = 1.48, p > 0.05). For
STN, the same pattern of activity existed (Figure 4C, right;
t(18) = 0.65, p > 0.05). Further, M1 exhibited higher beta
band power during epochs of TJMs and no TJMs as compared
to STN (TJM: t(18) = 2.76, p < 0.05; no TJM: t(18) = 3.12,
p < 0.05). Moreover, TJM epochs exhibited lower centroid beta
band frequency compared to no TJM epochs for both M1 and
STN (Figure 4D; M1: t(18) =−2.84, p< 0.05; STN: t(18) =−3.57,
p < 0.05, respectively). Further, beta band frequency was higher
in M1 during TJM epochs compared to STN (t(18) = 3.63,
p < 0.05). Alternatively, there was no difference in beta band
frequency between M1 and STN during periods of quiescence
(t(18) =−0.47, p> 0.05).
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FIGURE 3 | Power in tremor frequency band increases during TJMs in M1 and STN. (A) Raw (top) and bandpass filtered (3–7 Hz; middle) M1 LFP traces
during epochs of TJMs (red) and no TJMs (blue) for the same representative animal presented in Figure 2. (A, bottom): Corresponding spectrograms for the raw M1
signal presented in the top panel of (A) during TJM and no TJM epochs. Overall, the spectrograms of raw and unfiltered signal indicate rhythmicity in the LFP during
periods of TJMs that is lacking during periods of quiescence. (A, right): Power spectrum of the bandpass filtered LFP signal presented in the middle panel of
(A) during the TJM (red) and no TJM (blue) epoch. Tremor frequency power increases substantially during periods of TJMs, while little tremor power exists during
epochs of quiescence. (B) Same as (A), but for a simultaneously recorded STN site for the same representative animal presented in (A). (C) Summary data for
tremor frequency power across all animals for TJM and no TJM epochs for M1 and STN. As can be seen, tremor band power dominates during the presence of
TJMs, but not for bouts lacking TJMs for both M1 and STN recording sites. (D) Summary data across all animals for tremor band centroid frequency as a function of
TJM and no TJM epochs for M1 and STN recording sites. Overall, there were no differences in centroid frequency across behavioral state or brain area.
DISCUSSION
Pilocarpine is a well known tremorogenic agent, and previous
studies have shown that pilocarpine-induced TJMs are reduced
by antiparkinsonian drugs (Salamone et al., 2005; Betz et al.,
2009; Collins et al., 2010; Podurgiel et al., 2013a), conditional
neural knockout of adenosine A2A receptors (Salamone et al.,
2013), and deep brain stimulation of the STN (Collins-
Praino et al., 2013). Pilocarpine-induced TJMs are central
in origin, and depend upon stimulation of M2 or M4
muscarinic receptors in the ventrolateral neostriatum of the
rat, which is the homolog of the ventral putamen of primates
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FIGURE 4 | Beta band power does not increase during TJMs in M1 and STN. (A) Raw (top) and bandpass filtered (15–30 Hz; middle) M1 LFP traces during
epochs of TJMs (red) and no TJMs (blue) for the same representative animal presented in Figures 2, 3. (A, bottom): The first 1.4 s of the middle panel of (A) to show
instantaneous LFP fluctuations. (A, right): Power spectrum of the bandpass filtered LFP signal presented in the middle panel of (A) during the TJM and no TJM
epoch. Beta frequency power does not increase during periods of TJMs. (B) Same as (A), but for a simultaneously recorded STN site for the same representative
animal presented in (A). (C) Summary data for beta band power across all animals for TJM and no TJM epochs for M1 and STN. As can be seen, beta band power
is similar across behavioral states. (D) Summary data across all animals for beta band centroid frequency as a function of TJM and no TJM epochs for M1 and STN
recording sites.
(Mayorga et al., 1997, 1999; Salamone et al., 1998). Pilocarpine
was employed in the present studies in order to induce a
robust TJM response that would allow for the assessment
of tremor-related EMG activity recorded simultaneously with
cortical and subthalamic LFP activity. The temporalis muscle
was used for the EMG measurements because of previous
research indicating that activity of this jaw closing muscle
is a critical marker of observable TJM activity (Cousins
et al., 1998). As described above, the induction of TJMs
by pilocarpine was associated with strong rhythmicity in
the envelope of the temporalis EMG signal, with a peak
frequency of approximately 4 Hz, along with robust second
and third harmonics (Figure 2). This is consistent with
EMG recordings from the forearms of PD patients during
periods of tremor (Liu et al., 2002; Timmermann et al., 2003;
Wang et al., 2005; Reck et al., 2009; Hirschmann et al.,
2013).
These data are consistent with previous results from
both clinical and preclinical studies, which indicate that
cholinomimetic-induced TJMs share characteristics with
human Parkinsonian tremor. Cholinomimetic drugs, including
muscarinic agonists and anticholinesterases, can induce or
exacerbate resting tremor in humans. Administration of the
anticholinesterase physostigmine to PD patients was reported
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to exacerbate Parkinsonian symptoms, including tremor, and
these motor deficits were attenuated by co-administration
of centrally-acting muscarinic antagonists (Duvoisin, 1967).
For many decades, muscarinic receptor antagonists have
been used to treat idiopathic and drug-induced Parkinsonism
(McEvoy, 1983). Anticholinesterases are prescribed to treat
the cognitive deficits associated with Alzheimer’s Disease (for
review, see Birks, 2006), and these drugs have been shown
to induce or exacerbate Parkinsonian symptoms, including
tremor, as side effects (Ott and Lannon, 1992; Keltner,
1994; Shea et al., 1998; Arai, 2000; Aarsland et al., 2003;
Gurevich et al., 2006; Song et al., 2008). In rodent studies,
muscarinic agonists and anticholinesterases induce TJMs, and
co-administration of antiparkinsonian agents including DA
agonists, L-DOPA, muscarinic antagonists, and adenosine
A2A antagonists have been shown to reduce cholinomimetic-
induced TJMs (Mayorga et al., 1997; Salamone et al., 1998,
2013, 2015a,b; Simola et al., 2004, 2006; Miwa et al., 2009;
Collins et al., 2010; Collins-Praino et al., 2011; Yasuda et al.,
2015).
In the present studies, tremor-related EMG activity was
accompanied by an increase in power at tremor frequency
(3–7 Hz) in M1 and the STN (Figure 3). In PD patients,
pathological oscillatory neuronal activity in the open and closed
loop connections between the cortex, basal ganglia, and thalamus
is thought to underlie tremorogenesis (Hutchison et al., 2004).
The development of tremor has been associated with the
emergence of oscillations in the tremor frequency range (3–7 Hz)
as indicated by power spectra of STN LFPs, and coherence
between STN LFPs and EMG activity at tremor frequency (Levy
et al., 2000; Brown et al., 2001; Liu et al., 2002; Wang et al.,
2005; Reck et al., 2009; Hirschmann et al., 2013; Oswal et al.,
2013). In a recent study (Hirschmann et al., 2013), the emergence
of tremor in PD patients was shown to be associated with an
increase of cerebral synchronization at tremor frequency and
the second harmonic in a network that includes both STN
and M1. In African green monkeys treated with 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the development
of resting tremor was associated with the emergence of
oscillations at tremor frequency in the STN (Bergman et al.,
1994). Furthermore, previous studies have observed a strong
coherence between EMG of forearm muscles and M1 activity at
tremor frequency and its second harmonic (Timmermann et al.,
2003).
In contrast to the observed association between TJM-related
EMG recordings and LFP activity in the tremor frequency range
(Figure 3), tremor activity was not specifically associated with
increased synchrony in the beta frequency band in either M1 or
STN (Figure 4). Oscillatory activity in the STN of PD patients has
been well characterized, as researchers are able to record LFPs
from patients undergoing implantation of electrodes for deep
brain stimulation. In recent years, considerable focus has been
on increased oscillatory activity in the beta band (∼15–30 Hz),
since there is evidence that increased beta power in the STN
is associated with motor control, particularly akinesia-rigidity
(Brown et al., 2001; Levy et al., 2002; Priori et al., 2004; Brown
and Williams, 2005; Kühn et al., 2006). Nevertheless, resting
tremor has not been shown to correlate with beta band activity
in the STN of PD patients (Kühn et al., 2006). Thus, the
results from our experiments in rats are line with the findings
reported in the clinical and non-human primate studies, as we
observed increased power in the tremor frequency range in
M1 and STN during periods of tremor activity, but did not
observe increased power in the beta frequency range during
periods of TJMs.
The present results are consistent with previous studies
demonstrating that the STN is a critical part of the basal
ganglia circuitry that is involved in motor dysfunctions related
to Parkinsonism. STN neurons were reported to show alterations
in firing pattern and hyperactivity in Parkinsonian primates
treated with MPTP (Miller and DeLong, 1987). In human
PD patients, synchronized high-frequency (i.e., 15–30 Hz)
oscillations have been recorded from the STN (Levy et al.,
2000). STN high-frequency stimulation has been shown to
improve akinesia, rigidity, postural and gait instabilities, and
tremor in patients with PD (Limousin et al., 1995; Deuschl
et al., 2006; Moro et al., 2010). Moreover, L-DOPA was
reported to enhance the antiparkinsonian efficacy of STN
stimulation (Bejjani et al., 2000). Lesions or inactivation of
STN have been shown to reverse motor dysfunctions in
rodent models (Centonze et al., 2005; Baunez and Gubellini,
2010). In addition, high frequency stimulation of STN has
been reported to restore motor function in rodent models
of Parkinsonism (Baunez, 2011; Brown et al., 2011), and to
attenuate drug-induced TJMs in rats (Collins-Praino et al.,
2013).
Network activation as measured by LFP activity in M1
and STN can be used as a tool to better understand
transient dynamics across distributed neural networks. For
example, abnormalities in long-range connectivity between brain
areas have been postulated as important pathophysiological
mechanisms underlying brain dysfunctions (Hutchison et al.,
2004; Mallet et al., 2008). Detailed analysis of signals such as
the LFP and EEG can reveal the engagement of distributed
neural circuits in relation to tremorogenesis. However, it remains
unclear how perturbed connectivity relates to motor symptoms
such as tremorogenesis, and how it is manifested in the
dynamic interactions of neuronal circuits. For that reason,
it is important to study tremor-related oscillatory activity by
using animal models that allow for the investigation of the
specific circuits and neural mechanisms involved. Although
oscillatory neural activity has been well documented in the
clinical literature related to Parkinsonism, very little has been
done to study these oscillatory alterations in rodent models.
LFPs recorded from the frontal cortex and STN of rats
with 6-OHDA lesions of midbrain dopaminergic neurons
show increased power and coherence in the beta frequency
band (Sharott et al., 2005; Mallet et al., 2008). However, it
should be noted that these studies were using a model that
involved neurotoxic depletion of DA, and were not specifically
designed to focus on tremor-related activity. In contrast,
our study employed a model of drug-induced Parkinsonian
resting tremor; though the pilocarpine-treated rats appeared
to have reduced locomotion after pilocarpine administration,
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they were not completely akinetic, and occasionally moved
about the chamber during recording. Therefore, our study
specifically evaluated the physiological correlates of tremor by
using an agent that induces a robust tremorogenic (i.e., TJM)
response.
In summary, pilocarpine-induced TJMs, which share several
characteristics with Parkinsonian tremor (Salamone et al., 1998;
Collins-Praino et al., 2011), are accompanied by rhythmic
oscillatory neural activity in the tremor frequency range in
both STN and M1. In view of the fact that the TJM model
is frequently used to characterize novel drugs for their ability
to suppress tremor (Collins et al., 2010, 2012; Santerre et al.,
2012; Podurgiel et al., 2013a), it has been suggested that
the combination of physiological and behavioral measures of
tremor could be employed in preclinical studies focused on
characterizing the neural circuitry that underlies tremorogenesis,
and for the assessment of treatments that specifically target
tremor (Salamone et al., 2015a).
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FIGURE S1 | Verification of electrode placements across all animals.
(A) M1 electrode placement termination points (red dots) across five rats
(rows). (B) Same as for (A), but for STN electrodes. Each animal
simultaneously contributed 3–4 M1 and STN placements (Rat one contributed
three electrodes for each areal region, while all other animals contributed 4) for
a total of 19 M1 electrodes and 19 STN electrodes across five animals
(n = 38). M1 placements ranged from AP: +0.72 to +2.28 mm (relative to
Bregma), while STN placements ranged from AP: −3.24 to +3.96 mm (relative
to Bregma).
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